U.S. RESEARCH ROUNDUP-American Express, Cintas, Kimberly-Clark

Reuters03-28

March 28 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including American Express, Cintas, and Kimberly-Clark on Thursday.

HIGHLIGHTS

* American Express Co : Evercore ISI raises target price to $243 from $229

* Cintas Corp : Jefferies raises target price to $665 from $554

* Kimberly-Clark Corp : Piper Sandler raises target price to $152 from $145

Following is a summary of research actions on U.S. companies reported by Reuters on Thursday. Stock entries are in alphabetical order.

* Ally Financial Inc : Evercore ISI raises target price to $43 from $41

* American Express Co : Evercore ISI raises target price to $243 from $229

* Braze Inc : Canaccord Genuity cuts target price to $65 from $70

* Braze Inc : JP Morgan cuts target price to $58 from $60

* Braze Inc : Raymond James cuts target price to $65 from $75

* $Capital One Financial Corp(COF-N)$ : Evercore ISI raises target price to $155 from $142

* Carlisle Companies Inc : Jefferies raises target price to $400 from $350

* Carnival Corp : JP Morgan raises target price to $23 from $22

* Carnival Corp : Macquarie raises target price to $24 from $22

* Cintas Corp : Jefferies raises target price to $665 from $554

* Cintas Corp : RBC raises target price to $725 from $675

* Citizens Financial : Evercore ISI raises target price to $39 from $35

* Comerica Inc : Evercore ISI raises target price to $58 from $55

* Cullen/Frost Bankers Inc : Evercore ISI raises target price to $113 from $109

* Deciphera Pharmaceuticals Inc : Jefferies raises target price to $26 from $21

* Dnow Inc : Stifel raises target price to $18 from $16

* Elevance Health Inc : Jefferies reinstates coverage with buy rating; PT $602

* Evolent Health Inc : Canaccord Genuity cuts target price to $44 from $45

* Fifth Third Bancorp : Evercore ISI raises target price to $40 from $37

* First Horizon Corp : Evercore ISI raises target price to $17.5 from $17

* Goosehead Insurance Inc : Piper Sandler raises target price to $88 from $85

* Huntington Bancshares Inc : Evercore ISI raises target price to $16 from $15

* Jasper Therapeutics Inc : RBC initiates coverage with outperform rating; PT $70

* Keycorp : Evercore ISI raises target price to $18.00 from $17.00

* Kimberly-Clark Corp : Piper Sandler raises target price to $152 from $145

* M&T Bank Corp : Evercore ISI raises target price to $157.00 from $146.00

* Matador Resources Co : Roth MKM raises target price to $71

* Metagenomi Technologies Llc : Jefferies cuts target price to $22 from $23

* Moderna Inc : Jefferies raises target price to $125 from $115

* PNC Financial Services Group Inc : Evercore ISI raises PT to $184.00 from $180.00

* Progress Software Corp : D.A. Davidson initiates with buy rating and $65 PT

* Regions Financial Corp : Evercore ISI raises target price to $22 from $20

* RH : Jefferies raises target price to $318 from $269

* RH : JP Morgan raises target price to $345 from $329

* Sprinklr Inc : Barclays raises target price to $17 from $15

* Synchrony Financial : Evercore ISI raises target price to $47.00 from $45.00

* Synovus Financial Corp : Evercore ISI raises target price to $42 from $40

* US Bancorp : Evercore ISI raises target price to $48 from $46

* Viatris Inc : Piper Sandler raises target price to $13 from $11

* Wells Fargo & Co : Evercore ISI raises target price to $67 from $58

* Zions Bancorporation Na : Evercore ISI raises target price to $48 from $47

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment